Navigation Links
Osteologix Announces Completion of Corporate Consolidation
Date:8/5/2011

DUBLIN, August 5, 2011 /PRNewswire/ --

Osteologix Holdings, PLC ("Osteologix" or the "Company") stated that its previously announced plans to consolidate its operations in Ireland have been completed.  All operations at the former location in Virginia have ceased.  Its former parent, Osteologix, Inc. has been dissolved and all former shareholders as of the exchange date of July 26, 2011 will receive an equal number of shares of Osteologix Holdings PLC.  Shares of the Company stock are traded on the Pink Sheets under the ticker symbol OLGXF.

The Company is seeking to minimize its corporate overhead expense, while focusing its business activities on maximizing the value of the Company's licensing agreement with the Servier Research Group and continuing to seek development partners in the United States for NB S101, its product candidate for the treatment of osteoporosis.  

Assuming the continued milestone payments, and the anticipated royalties from the Company's license agreement with the Servier Research Group, Osteologix looks forward to operating on a positive cash flow basis with the potential for dividend payments to shareholders possibly beginning in late 2011.

David O'Flynn is Managing Director of Osteologix Holdings PLC and can be contacted at the address below.

About Osteoporosis

The World Health Organization defines osteoporosis as a progressive skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue with a consequential increase in bone fragility and susceptibility to fracture. There is increased risk of fracture particularly of spine, hip, pelvis and forearm. It is predominantly a disease of post-menopausal women and risk of fracture increases with age. Fractures caused by osteoporosis affect one in two women and one in five men over the age of 50.

About NB S101

NB S101 is a novel dual acting bone agent, or DABA, the active component of which significantly improves bone mineral density and reduces fracture risk.  NB S101 has demonstrated significant beneficial effects in a Phase 2 clinical trial by reducing bone resorption and increasing strong bone formation. This dual action on bone- a significant medical need not served by current therapies in the U.S.- suggests that NB S101 could fundamentally change the treatment paradigm of patients with osteoporosis.  Importantly, NB S101 appears to help build bone in a manner similar to the body's own metabolic processes by rebalancing bone metabolism in a way that favors strong bone formation.  Key patents for NB S101 have been issued in the United States, Europe and Japan, providing protection to at least 2024.

About Osteologix
Osteologix is a specialty pharmaceutical company focused on the development of innovative therapies for the treatment and prevention of diseases of bone and joint tissues. Its lead product candidate, NB S101, is a novel pharmaceutical agent for the treatment and prevention of osteoporosis. In November 2007, Osteologix completed a Phase II clinical trial of NB S101 that demonstrated the ability of NB S101 to reduce markers of bone resorption and increase bone mineral density. In July, 2010 Osteologix granted the Servier Research Group an exclusive royalty bearing license to develop and commercialize NB S101 (strontium malonate) and other strontium salts covered by Osteologix's patent rights to treat post menopausal osteoporosis, other bone and joint disorders and dental indications worldwide, except in the U.S. For more information please visit http://www.osteologix.com.

Safe Harbor Statement:
Statements in this press release are not strictly historical, including statements about the corporate consolidation, operating on a positive cash flow basis, the payment and timing of any potential dividends, potential payments and royalties from Servier and their impact on Osteologix's finances, the potential uses and benefits or NB S101, Servier's potential commercial launch of NB S101, and patent protection of NB S101 are forward-looking statements made pursuant to the safe-harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected or assumed in such forward-looking statements, including, without limitation,  Osteologix's obligations to Aditech Pharma AB, risks related to Servier's ability to conduct additional clinical trials of NB S101, Servier's ability to obtain approval from government authorities for the sale and distribution of NB S101, Servier's compliance with terms of our agreement, market acceptance of NB S101 and potential success and introduction of competing products. Additional factors that could cause actual results to differ materially are included under the heading "Risk Factors" in Part II, Item 1A of the Osteologix, Inc. Quarterly Report on Form 10-Q filed November 15, 2010. All forward-looking statements and risk factors included in this document are made as of the date hereof, based on information available to us as of the date hereof, and we assume no obligation to update any forward-looking statement or risk factor. You should consult the risk factors listed in the Osteologix, Inc. Annual Report on Form 10-K and in the Osteologix, Inc. Quarterly Reports previously filed on Form 10-Q.


'/>"/>
SOURCE Osteologix Holdings, PLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
(Date:6/23/2016)... Francisco, CA (PRWEB) , ... June 23, 2016 ... ... (EDC) software, is exhibiting at the Pennsylvania Convention Center and will showcase its ... Annual conference. ClinCapture will also be presenting a scientific poster on Disrupting Clinical ...
(Date:6/23/2016)... , June 22, 2016  Amgen (NASDAQ: ... of the QB3@953 life sciences incubator to ... health. The shared laboratory space at QB3@953 was created ... a key obstacle for many early stage organizations - ... of the sponsorship, Amgen launched two "Amgen Golden Ticket" ...
(Date:6/22/2016)... 22, 2016 Research and Markets has announced ... report to their offering. ... from $29.3 billion in 2013. The market is expected to grow ... 2015 to 2020, increasing from $50.6 billion in 2015 to $96.6 ... during the forecast period (2015 to 2020) are discussed. As well, ...
Breaking Biology Technology:
(Date:5/20/2016)... , May 20, 2016  VoiceIt is ... partnership with VoicePass. By working together, ... experience.  Because VoiceIt and VoicePass take slightly different ... engines increases both security and usability. ... excitement about this new partnership. "This ...
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
Breaking Biology News(10 mins):